Azithromycin Reduces Gastroesophageal Reflux and Aspiration in Lung Transplant Recipients

  • V. Mertens
  • K. Blondeau
  • A. Pauwels
  • R. Farre
  • B. Vanaudenaerde
  • R. Vos
  • G. Verleden
  • D. E. Van Raemdonck
  • L. J. Dupont
  • D. SifrimEmail author
Original Article


Azithromycin (AZI) is a macrolide antibiotic that improves lung function in lung transplant recipients (LTx). Gastroesophageal reflux (GER) has been implicated in the pathogenesis of chronic rejection after LTx. Macrolide antibiotics may affect GER by modifying esophageal and gastric motility. The purpose of this study was to evaluate the effect of AZI on GER and gastric aspiration after LTx. Acid and weakly acidic GER was measured with 24-h pH-impedance monitoring in 47 LTx patients (12 patients “on” AZI). Gastric aspiration was assessed in a separate group of 30 LTx patients before and after AZI by measurements of pepsin and bile acid in bronchoalveolar lavage fluid (BALF). Patients “on” AZI had a significant lower total number of reflux events [41 (30–61) vs. 22.5 (7–37.5)], number of acid reflux events [24 (16–41) vs. 8 (4–18)], esophageal acid exposure [2.9% (0.7–7.3) vs. 0.2% (0.1–2.0)], bolus exposure [0.73% (0.5–1.4) vs. 0.21% (0.12–0.92)], and proximal extent of reflux [14 (9–24) vs. 5 (2–7)]. AZI reduced the concentration of bile acids in BALF without affecting levels of pepsin. LTx patients “on” AZI have less GER and bile acids aspiration. This effect might be due to enhanced esophageal motility and accelerated gastric emptying.


Lung transplant recipients Azithromycin Gastroesophageal reflux Bile acids 


  1. 1.
    Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981;123(4 Pt 1):413–417.PubMedGoogle Scholar
  2. 2.
    Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24-hour pressure, pH, and impedance monitoring. Gut. 2005;54(4):449–454. doi: 10.1136/gut.2004.055418.PubMedCrossRefGoogle Scholar
  3. 3.
    Feigelson J, Sauvegrain J. Letter: Gastro-esophageal reflux in mucoviscidosis. Nouv Presse Med. 1975;4(38):2729–2730.PubMedGoogle Scholar
  4. 4.
    Blondeau K, Dupont L, Mertens V, Verleden G, Malfroot A, Vandenplas Y, Hauser B, Sifrim D. Gastroesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut. 2008;57:1049–1055.Google Scholar
  5. 5.
    Rosztoczy A, Makk L, Izbeki F, Roka R, Somfay A, Wittmann T. Asthma and gastroesophageal reflux: clinical evaluation of esophago-bronchial reflex and proximal reflux. Digestion. 2008;77(3–4):218–224. doi: 10.1159/000146083.PubMedCrossRefGoogle Scholar
  6. 6.
    Harding SM. The potential role of gastroesophageal reflux in asthma. Minerva Gastroenterol Dietol. 2001;47(2):75–83.PubMedGoogle Scholar
  7. 7.
    Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008;31(4):707–713. doi: 10.1183/09031936.00064807.PubMedCrossRefGoogle Scholar
  8. 8.
    D’Ovidio F, Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus. 2006;19(5):315–320. doi: 10.1111/j.1442-2050.2006.00603.x.PubMedCrossRefGoogle Scholar
  9. 9.
    Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest. 2000;118(4):1214–1217. doi: 10.1378/chest.118.4.1214.PubMedCrossRefGoogle Scholar
  10. 10.
    Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest. 2003;124(5):1689–1693. doi: 10.1378/chest.124.5.1689.PubMedCrossRefGoogle Scholar
  11. 11.
    Stordal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child. 2005;90(9):956–960. doi: 10.1136/adc.2004.068890.PubMedCrossRefGoogle Scholar
  12. 12.
    Jiang SP, Liang RY, Zeng ZY, Liu QL, Liang YK, Li JG. Effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease. World J Gastroenterol. 2003;9(5):1123–1125.PubMedGoogle Scholar
  13. 13.
    Bocskei C, Viczian M, Bocskei R, Horvath I. The influence of gastroesophageal reflux disease and its treatment on asthmatic cough. Lung. 2005;183(1):53–62. doi: 10.1007/s00408-004-2526-z.PubMedCrossRefGoogle Scholar
  14. 14.
    Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. Eur Respir J. 2000;16(4):633–638. doi: 10.1034/j.1399-3003.2000.16d11.x.PubMedCrossRefGoogle Scholar
  15. 15.
    Tutuian R, Mainie I, Agrawal A, Adams D, Castell DO. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest. 2006;130(2):386–391. doi: 10.1378/chest.130.2.386.PubMedCrossRefGoogle Scholar
  16. 16.
    Mainie I, Tutuian R, Agrawal A, et al. Fundoplication eliminates chronic cough due to non-acid reflux identified by impedance pH monitoring. Thorax. 2005;60(6):521–523. doi: 10.1136/thx.2005.040139.PubMedCrossRefGoogle Scholar
  17. 17.
    Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg. 2007;42(8):1341–1344. doi: 10.1016/j.jpedsurg.2007.03.030.PubMedCrossRefGoogle Scholar
  18. 18.
    Cantu E III, Appel JZ III, Hartwig MG, et al. J. Maxwell Chamberlain memorial paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4):1142–1151. doi: 10.1016/j.athoracsur.2004.04.044.PubMedCrossRefGoogle Scholar
  19. 19.
    Hartwig MG, Appel JZ, Davis RD. Antireflux surgery in the setting of lung transplantation: strategies for treating gastroesophageal reflux disease in a high-risk population. Thorac Surg Clin. 2005;15(3):417–427. doi: 10.1016/j.thorsurg.2005.03.001.PubMedCrossRefGoogle Scholar
  20. 20.
    O’Halloran EK, Reynolds JD, Lau CL, et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J Gastrointest Surg. 2004;8(1):132–137. doi: 10.1016/j.gassur.2003.10.1013.PubMedCrossRefGoogle Scholar
  21. 21.
    Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther. 2000;14(5):561–569. doi: 10.1046/j.1365-2036.2000.00742.x.PubMedCrossRefGoogle Scholar
  22. 22.
    Fink SM, Lange RC, McCallum RW. Effect of metoclopramide on normal and delayed gastric emptying in gastroesophageal reflux patients. Dig Dis Sci. 1983;28(12):1057–1061. doi: 10.1007/BF01295802.PubMedCrossRefGoogle Scholar
  23. 23.
    McCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology. 1983;84(6):1573–1577.PubMedGoogle Scholar
  24. 24.
    Takeda T, Konomi H, Naritomi G, et al. Single oral dose of cisapride accelerates gastric antral emptying in healthy humans: an ultrasonographic study. J Gastroenterol. 1996;31(3):323–328. doi: 10.1007/BF02355019.PubMedCrossRefGoogle Scholar
  25. 25.
    Campo S, Morini S, Re MA, et al. Esophageal dysmotility and gastroesophageal reflux in intrinsic asthma. Dig Dis Sci. 1997;42(6):1184–1188. doi: 10.1023/A:1018841704897.PubMedCrossRefGoogle Scholar
  26. 26.
    Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol. 1999;94(6):1464–1467. doi: 10.1111/j.1572-0241.1999.1127_e.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child. 1991;66(11):1339–1345. doi: 10.1136/adc.66.11.1339.PubMedCrossRefGoogle Scholar
  28. 28.
    Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest. 2003;123(3):679–684. doi: 10.1378/chest.123.3.679.PubMedCrossRefGoogle Scholar
  29. 29.
    Vandenplas Y. Clinical use of cisapride and its risk-benefit in paediatric patients. Eur J Gastroenterol Hepatol. 1998;10(10):871–881. doi: 10.1097/00042737-199810000-00011.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen CL, Orr WC, Verlinden MH, et al. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(4):749–757. doi: 10.1046/j.1365-2036.2002.01218.x.PubMedCrossRefGoogle Scholar
  31. 31.
    Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(8):1481–1490. doi: 10.1046/j.1365-2036.2002.01324.x.PubMedCrossRefGoogle Scholar
  32. 32.
    Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121–125. doi: 10.1164/rccm.200212-1424BC.PubMedCrossRefGoogle Scholar
  33. 33.
    Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77(9):1465–1467. doi: 10.1097/01.TP.0000122412.80864.43.PubMedCrossRefGoogle Scholar
  34. 34.
    Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172(6):772–775. doi: 10.1164/rccm.200411-1537OC.PubMedCrossRefGoogle Scholar
  35. 35.
    Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566–570. doi: 10.1164/rccm.200601-071OC.PubMedCrossRefGoogle Scholar
  36. 36.
    Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297–310. doi: 10.1016/S1053-2498(02)00398-4.PubMedCrossRefGoogle Scholar
  37. 37.
    Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53(7):1024–1031. doi: 10.1136/gut.2003.033290.PubMedCrossRefGoogle Scholar
  38. 38.
    Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther. 2005;22(10):1011–1021. doi: 10.1111/j.1365-2036.2005.02677.x.PubMedCrossRefGoogle Scholar
  39. 39.
    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829–1832.PubMedGoogle Scholar
  40. 40.
    Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol. 2001;31(6):464–473. doi: 10.1002/ppul.1076.PubMedCrossRefGoogle Scholar
  41. 41.
    Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1):36–41.PubMedCrossRefGoogle Scholar
  42. 42.
    D’Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg. 2005;129(5):1144–1152. doi: 10.1016/j.jtcvs.2004.10.035.PubMedCrossRefGoogle Scholar
  43. 43.
    D’Ovidio F, Mura M, Ridsdale R, et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant. 2006;6(8):1930–1938. doi: 10.1111/j.1600-6143.2006.01357.x.PubMedCrossRefGoogle Scholar
  44. 44.
    Hadjiliadis D, Duane DR, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant. 2003;17(4):363–368. doi: 10.1034/j.1399-0012.2003.00060.x.PubMedCrossRefGoogle Scholar
  45. 45.
    Palmer SM. Reflux of bile acids: an innate problem of lung transplantation. Am J Transplant. 2006;6(8):1757–1758. doi: 10.1111/j.1600-6143.2006.01425.x.PubMedCrossRefGoogle Scholar
  46. 46.
    Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003;125(3):533–542. doi: 10.1067/mtc.2003.166.PubMedCrossRefGoogle Scholar
  47. 47.
    Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology. 1993;105(6):1886–1899.PubMedGoogle Scholar
  48. 48.
    Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005;313(3):1397–1405. doi: 10.1124/jpet.104.081497.PubMedCrossRefGoogle Scholar
  49. 49.
    Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. Nat Clin Pract Gastroenterol Hepatol. 2006;3(4):210–219. doi: 10.1038/ncpgasthep0446.PubMedCrossRefGoogle Scholar
  50. 50.
    Bala I, Prasad K, Bhukal I, Nakra D, Pratap M. Effect of preoperative oral erythromycin, erythromycin-ranitidine, and ranitidine-metoclopramide on gastric fluid pH and volume. J Clin Anesth. 2008;20(1):30–34. doi: 10.1016/j.jclinane.2007.08.002.PubMedCrossRefGoogle Scholar
  51. 51.
    Asai T, Murao K, Shingu K. Pre-operative oral erythromycin reduces residual gastric volume and acidity. Br J Anaesth. 2000;85(6):861–864. doi: 10.1093/bja/85.6.861.PubMedCrossRefGoogle Scholar
  52. 52.
    Memis D, Turan A, Karamanlioglu B, et al. Effect of preoperative oral use of erythromycin and nizatidine on gastric pH and volume. Anaesth Intensive Care. 2002;30(4):428–432.PubMedGoogle Scholar
  53. 53.
    Clarke AT, Wirz AA, Manning JJ, Ballantyne SA, Alcorn DJ, McColl KE. Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket. Gut. 2008;57(3):292–297. doi: 10.1136/gut.2006.109421.PubMedCrossRefGoogle Scholar
  54. 54.
    Bisschops R, Sifrim D, Vos R, Janssens J, Tack J. Influence of gastric motility modifying drugs on the postprandial acid and bile pockets at the gastro-esophageal junction. Gastroenterology (in press).Google Scholar
  55. 55.
    Sifrim D, Matsuo H, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res. 1994;20(3):121–126.PubMedGoogle Scholar
  56. 56.
    Ward C, Forrest IA, Brownlee IA, et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax. 2005;60(10):872–874. doi: 10.1136/thx.2004.036426.PubMedCrossRefGoogle Scholar
  57. 57.
    Mertens V, Blondeau K, Vanaudenaerde BM, et al. Pepsin or bile acids: what is the best marker of gastric aspiration in lung transplant recipients? J Heart Lung Transplant. 2008;27(2):S125–S126. doi: 10.1016/j.healun.2007.11.188.CrossRefGoogle Scholar
  58. 58.
    Koek GH, Vos R, Sifrim D, Cuomo R, Janssens J, Tack J. Mechanisms underlying duodeno-gastric reflux in man. Neurogastroenterol Motil. 2005;17(2):191–199. doi: 10.1111/j.1365-2982.2004.00633.x.PubMedCrossRefGoogle Scholar
  59. 59.
    Fountos A, Chrysos E, Tsiaoussis J, et al. Duodenogastric reflux after biliary surgery: scintigraphic quantification and improvement with erythromycin. ANZ J Surg. 2003;73(6):400–403. doi: 10.1046/j.1445-2197.2003.t01-1-02654.x.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • V. Mertens
    • 1
  • K. Blondeau
    • 1
  • A. Pauwels
    • 1
  • R. Farre
    • 1
  • B. Vanaudenaerde
    • 2
  • R. Vos
    • 2
  • G. Verleden
    • 2
    • 3
  • D. E. Van Raemdonck
    • 3
  • L. J. Dupont
    • 2
    • 3
  • D. Sifrim
    • 1
    • 4
    Email author
  1. 1.Center for Gastroenterological ResearchCatholic University LeuvenLeuvenBelgium
  2. 2.Laboratory of PneumologyCatholic University LeuvenLeuvenBelgium
  3. 3.Lung Transplant Unit, University Hospital GasthuisbergCatholic University LeuvenLeuvenBelgium
  4. 4.Lab G-I Physiopathology, Faculty of MedicineCatholic University LeuvenLeuvenBelgium

Personalised recommendations